Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprostene Bunod vs Timolol on Retinal Vessel Density
NCT03931317Completed
- Sponsor
- University of California, San Diego
- Start
- Dec 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of latanoprostene bunod in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by University of California, San Diego. Primary endpoint: Change in retinal blood vessel density (peripapillary and macular) at 4 weeks. Started Dec 2018; status: completed.
02
Drugs
latanoprostene bunod
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03931317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931317.